STERISCIENCE
GenericsSTERISCIENCE is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular. Key products include FOCINVEZ.
STERISCIENCE's Key Drugs
STERISCIENCE's core commercial portfolio centers on FOCINVEZ, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
STERISCIENCE's Recent FDA Approvals
STERISCIENCE secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
STERISCIENCE's Therapeutic Areas
STERISCIENCE's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STERISCIENCE's Top Competitors
STERISCIENCE's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STERISCIENCE Pipeline Snapshot
Active clinical trials for STERISCIENCE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FOCINVEZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1964-11-06
- Latest
- 2026-09-25
- Applications
- 15